Aquila and Elan have also signed a supply contract for the adjuvant. Aquila has received a license payment and could receive additional fees and milestone payments plus royalties on future product sales. Elan will be responsible for product development and marketing of any products that are developed.
Neurological diseases affect several million people in the United States.
Stimulon adjuvant, enhances the body's immune response. The Company's products are intended for use in treating, controlling and preventing infectious diseases, cancers and autoimmune disorders. No part of this publication may be redistributed in any form without prior permission. Terms and conditions for users . Privacy policy .